Pu-erh Tea for Health & Longevity - Quick Reference Sheet

Pu-erh Tea for Health & Longevity

Created on 07/01/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Pu-erh is a fermented dark tea studied for modest effects on weight, blood fats, and blood sugar. Its fermentation pigment appears to lower cholesterol through the gut. Animal evidence is strong but human data are thin, so expectations should stay modest. Main cautions are caffeine, reduced iron absorption, and contamination from poor storage. (Full Review)

Protocol

Intake
2–4 cups/day
~3–5 g leaf per 150–250 mL serving, often after meals
Best Time
Morning to early afternoon
After-meal timing aligns with digestive and glucose goals
Dosing
Split across the day
2–4 servings rather than one large dose; extract studies used 333 mg 3×/day
Time to effect
Metabolic Effects
Weeks to months
Principal weight trial measured outcomes over 3 months
Alertness
Immediate
Within the hour, from caffeine content
Caffeine Half-Life
~4–6 hours
Longer in slow metabolizers and pregnancy; informs avoiding late-day intake

Benefits

Contraindications
  • Iron-deficiency anemia
  • Uncontrolled hypertension
  • Significant cardiac arrhythmia
  • Anxiety disorders
  • Known caffeine intolerance
  • Pregnancy and breastfeeding (limit caffeine, ~200 mg/day cap)
Key Interactions
  • Stimulant or sympathomimetic medications
  • Quinolone antibiotics (ciprofloxacin), fluvoxamine
  • Anticoagulants (warfarin)
  • Caffeine-containing OTC products
  • Iron supplements
  • Glucose-lowering drugs (acarbose, insulin)
  • Other stimulant supplements (synephrine, yohimbine)

Risk & Side Effects

  • High: Caffeine-related effects
  • Medium: Contaminants: heavy metals and aluminum; mycotoxin and microbial contamination
  • Low: Gastrointestinal upset and tannin effects
  • Speculative: Liver effects at extreme concentrated intake

Monitoring

Marker Target Why
Total cholesterol < 200 mg/dL (functional < 180) Primary lipid endpoint pu-erh may influence
LDL cholesterol < 100 mg/dL (functional < 80 for higher-risk) Main cholesterol fraction targeted by the bile-acid mechanism
HDL cholesterol > 50 mg/dL (women), > 40 (men); functional > 60 Protective fraction; context for overall lipid change
Triglycerides < 100 mg/dL (conventional < 150) Sensitive to diet and metabolic status
Fasting glucose 70–90 mg/dL (conventional < 100) Tracks the post-meal glucose-blunting mechanism
HbA1c < 5.4% (conventional < 5.7%) Longer-term blood-sugar control
Body weight / BMI BMI 18.5–24.9 (individualized) Primary endpoint in the main human trial
Ferritin / iron studies Ferritin ~50–150 ng/mL Detects tannin-related iron-absorption impact
Blood pressure < 120/80 mmHg Caffeine can transiently raise BP

Cadence: Baseline before starting, then at ~3 months, then every 6–12 months

Qualitative Assessment

  • Sleep quality and time to fall asleep (caffeine sensitivity check)
  • Energy levels and afternoon alertness
  • Digestive comfort after meals
  • Anxiety or jitteriness as a sign of excess caffeine
  • Appetite and post-meal satiety